These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
215 related articles for article (PubMed ID: 37390702)
41. Rescue of Mitochondrial Function in Hutchinson-Gilford Progeria Syndrome by the Pharmacological Modulation of Exportin CRM1. Monterrubio-Ledezma F; Navarro-García F; Massieu L; Mondragón-Flores R; Soto-Ponce LA; Magaña JJ; Cisneros B Cells; 2023 Jan; 12(2):. PubMed ID: 36672210 [TBL] [Abstract][Full Text] [Related]
42. Mechanisms of angiogenic incompetence in Hutchinson-Gilford progeria via downregulation of endothelial NOS. Gete YG; Koblan LW; Mao X; Trappio M; Mahadik B; Fisher JP; Liu DR; Cao K Aging Cell; 2021 Jul; 20(7):e13388. PubMed ID: 34086398 [TBL] [Abstract][Full Text] [Related]
43. Towards a Drosophila model of Hutchinson-Gilford progeria syndrome. Beard GS; Bridger JM; Kill IR; Tree DR Biochem Soc Trans; 2008 Dec; 36(Pt 6):1389-92. PubMed ID: 19021561 [TBL] [Abstract][Full Text] [Related]
44. Plasma Progerin in Patients With Hutchinson-Gilford Progeria Syndrome: Immunoassay Development and Clinical Evaluation. Gordon LB; Norris W; Hamren S; Goodson R; LeClair J; Massaro J; Lyass A; D'Agostino RB; Tuminelli K; Kieran MW; Kleinman ME Circulation; 2023 Jun; 147(23):1734-1744. PubMed ID: 36919608 [TBL] [Abstract][Full Text] [Related]
45. Activating the synthesis of progerin, the mutant prelamin A in Hutchinson-Gilford progeria syndrome, with antisense oligonucleotides. Fong LG; Vickers TA; Farber EA; Choi C; Yun UJ; Hu Y; Yang SH; Coffinier C; Lee R; Yin L; Davies BS; Andres DA; Spielmann HP; Bennett CF; Young SG Hum Mol Genet; 2009 Jul; 18(13):2462-71. PubMed ID: 19376814 [TBL] [Abstract][Full Text] [Related]
46. Naïve adult stem cells from patients with Hutchinson-Gilford progeria syndrome express low levels of progerin in vivo. Wenzel V; Roedl D; Gabriel D; Gordon LB; Herlyn M; Schneider R; Ring J; Djabali K Biol Open; 2012 Jun; 1(6):516-26. PubMed ID: 23213444 [TBL] [Abstract][Full Text] [Related]
47. Molecular and Cellular Mechanisms Driving Cardiovascular Disease in Hutchinson-Gilford Progeria Syndrome: Lessons Learned from Animal Models. Benedicto I; Dorado B; Andrés V Cells; 2021 May; 10(5):. PubMed ID: 34064612 [TBL] [Abstract][Full Text] [Related]
48. A targeted antisense therapeutic approach for Hutchinson-Gilford progeria syndrome. Erdos MR; Cabral WA; Tavarez UL; Cao K; Gvozdenovic-Jeremic J; Narisu N; Zerfas PM; Crumley S; Boku Y; Hanson G; Mourich DV; Kole R; Eckhaus MA; Gordon LB; Collins FS Nat Med; 2021 Mar; 27(3):536-545. PubMed ID: 33707773 [TBL] [Abstract][Full Text] [Related]
49. Hutchinson-Gilford Progeria Syndrome-Current Status and Prospects for Gene Therapy Treatment. Piekarowicz K; Machowska M; Dzianisava V; Rzepecki R Cells; 2019 Jan; 8(2):. PubMed ID: 30691039 [TBL] [Abstract][Full Text] [Related]
50. Blocking protein farnesylation improves nuclear shape abnormalities in keratinocytes of mice expressing the prelamin A variant in Hutchinson-Gilford progeria syndrome. Wang Y; Ostlund C; Worman HJ Nucleus; 2010; 1(5):432-9. PubMed ID: 21326826 [TBL] [Abstract][Full Text] [Related]
51. Small-Molecule Therapeutic Perspectives for the Treatment of Progeria. Macicior J; Marcos-Ramiro B; Ortega-Gutiérrez S Int J Mol Sci; 2021 Jul; 22(13):. PubMed ID: 34281245 [TBL] [Abstract][Full Text] [Related]
52. Vascular Smooth Muscle Cell-Specific Progerin Expression Provokes Contractile Impairment in a Mouse Model of Hutchinson-Gilford Progeria Syndrome that Is Ameliorated by Nitrite Treatment. Del Campo L; Sánchez-López A; González-Gómez C; Andrés-Manzano MJ; Dorado B; Andrés V Cells; 2020 Mar; 9(3):. PubMed ID: 32182706 [TBL] [Abstract][Full Text] [Related]
53. Aging in the Cardiovascular System: Lessons from Hutchinson-Gilford Progeria Syndrome. Hamczyk MR; del Campo L; Andrés V Annu Rev Physiol; 2018 Feb; 80():27-48. PubMed ID: 28934587 [TBL] [Abstract][Full Text] [Related]
55. Progerin impairs chromosome maintenance by depleting CENP-F from metaphase kinetochores in Hutchinson-Gilford progeria fibroblasts. Eisch V; Lu X; Gabriel D; Djabali K Oncotarget; 2016 Apr; 7(17):24700-18. PubMed ID: 27015553 [TBL] [Abstract][Full Text] [Related]
56. Temsirolimus Partially Rescues the Hutchinson-Gilford Progeria Cellular Phenotype. Gabriel D; Gordon LB; Djabali K PLoS One; 2016; 11(12):e0168988. PubMed ID: 28033363 [TBL] [Abstract][Full Text] [Related]
57. Systematic screening identifies therapeutic antisense oligonucleotides for Hutchinson-Gilford progeria syndrome. Puttaraju M; Jackson M; Klein S; Shilo A; Bennett CF; Gordon L; Rigo F; Misteli T Nat Med; 2021 Mar; 27(3):526-535. PubMed ID: 33707772 [TBL] [Abstract][Full Text] [Related]
58. Impact of MnTBAP and Baricitinib Treatment on Hutchinson-Gilford Progeria Fibroblasts. Vehns E; Arnold R; Djabali K Pharmaceuticals (Basel); 2022 Jul; 15(8):. PubMed ID: 36015093 [TBL] [Abstract][Full Text] [Related]
59. Farnesyltransferase inhibitor and rapamycin correct aberrant genome organisation and decrease DNA damage respectively, in Hutchinson-Gilford progeria syndrome fibroblasts. Bikkul MU; Clements CS; Godwin LS; Goldberg MW; Kill IR; Bridger JM Biogerontology; 2018 Dec; 19(6):579-602. PubMed ID: 29907918 [TBL] [Abstract][Full Text] [Related]
60. Presence and distribution of progerin in HGPS cells is ameliorated by drugs that impact on the mevalonate and mTOR pathways. Clements CS; Bikkul MU; Ofosu W; Eskiw C; Tree D; Makarov E; Kill IR; Bridger JM Biogerontology; 2019 Jun; 20(3):337-358. PubMed ID: 31041622 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]